Cargando…
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
OBJECTIVE: To investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role in mediating estrogen-dependant transcription. The study is a continuation of earlier work establishing the role of CITED1 in mammary gland developm...
Autores principales: | Dahlgren, Malin, Lettiero, Barbara, Dalal, Hina, Mårtensson, Kira, Gaber, Alexander, Nodin, Björn, Gruvberger-Saal, Sofia K., Saal, Lao H., Howlin, Jillian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268435/ https://www.ncbi.nlm.nih.gov/pubmed/37322548 http://dx.doi.org/10.1186/s13104-023-06376-1 |
Ejemplares similares
-
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours
por: Howlin, Jillian, et al.
Publicado: (2015) -
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
por: Dalal, Hina, et al.
Publicado: (2022) -
Molecular and genetic diversity in the metastatic process of melanoma
por: Harbst, Katja, et al.
Publicado: (2014) -
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
por: Dahlgren, Malin, et al.
Publicado: (2021) -
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
por: Olsson, Eleonor, et al.
Publicado: (2015)